期刊文献+

度他雄胺纳米悬浮液的制备 被引量:1

Preparation of dutasteride nanometer suspension
下载PDF
导出
摘要 目的运用高压均质技术制备度他雄胺纳米悬浮液。方法以粒径、多分散性和Zeta电位为考察指标,研究均质压力、循环次数、表面活性剂种类和浓度等因素对纳米悬浮液性质的影响,并考察度他雄胺的溶解度及药物溶出速率。结果均质压力是影响纳米粒径的主要因素。纳米尺度的度他雄胺的溶解度和体外溶出速率比原药明显提高。结论高压均质技术可以成功用于制备度他雄胺纳米悬浮液。 Objective To prepare dutasteride nanometer suspension by high pressure homogenization (HPH). Methods Using particle size, polydispersity, and Zeta electric potential as the investigation indexes, research was made in the effects of homogenization pressure, cycle indexes, and the species and concentration of surfactants on the quality of nanometer suspension. Moreover, the solubility and dissolution velocity of dutasteride were investigated. Results Homogenization pressure was the key factor that influenced the nanoparticle size. Compared with the solubility and dissolution velocity of the crude drug powder, those of dutasteride with nanoparticle were significantly improved. Conclusion High pressure homogenization technique can be successfully used to prepare dutasteride nanometer suspension.
出处 《西南国防医药》 CAS 2013年第12期1286-1288,共3页 Medical Journal of National Defending Forces in Southwest China
关键词 度他雄胺 纳米悬浮液 高压均质 dutasteride nanometer suspension high pressure homogenization
  • 相关文献

参考文献8

  • 1陈鸿杰,陈一戎.度他雄胺治疗良性前列腺增生的研究进展[J].中华男科学杂志,2011,17(1):63-67. 被引量:12
  • 2顾国良,袁峰.度他雄胺的药理作用与临床应用[J].医药导报,2005,24(3):214-215. 被引量:4
  • 3Liu G P,Zhang D R,Jiao Y.Comparison of different methods for preparation of a stable riccardin D formulation via nano-technology[J].Int J Pharm,2012,422:516-522.
  • 4Gao L,Liu G Y,Wang X Q,et al.Preparation of a chemically stable quercetin formulation using nanosuspension techonolgy[J].Int J Pharm,2010,404:231-237.
  • 5Chen H,Khemtong C,Yang X.Nanonization strategies for poorly water-souble drugs[J].Drug Discov Today,2011,16:354-360.
  • 6王恺源,高永良.度他雄胺PLGA微球的加速释放度试验研究[J].中国医药生物技术,2011,6(2):145-147. 被引量:2
  • 7Keck C M,Muller R H.Drug nanocrystrals of poorly soluble drugs produced by high pressure homogenization[J].Eur Pharm Biopharm,2006,62:3-16.
  • 8Van Eerdenbrugh B,Van den Mooter G.Top-down production of drug nanocrystals:nanosuspension stabilization,miniaturization and transformation into solid products[J].Int J Pharm,2008,364:64-75.

二级参考文献33

  • 1符旭东,高永良,平其能,汤韧.石杉碱甲乳酸-羟基醋酸共聚物微球的加速释放度试验研究[J].中国医院药学杂志,2005,25(11):1005-1008. 被引量:7
  • 2许云飞.多沙唑嗪、非那雄胺及其联合应用在BPH临床进展中的长期疗效[J].中华男科学杂志,2006,12(12):1149-1150. 被引量:1
  • 3Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology, 2002, 60(3) : 434-441.
  • 4Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology, 2004, 63(4) : 709-715.
  • 5Issa MM, Runken MC, Grogg AL, et al. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: Dutasteride versus finasteride. Am J Manag Care, 2007, 13 ( Suppl 1 ) : S10-S16.
  • 6Fenter TC, Davis EA, Shah MB, et al. Dutasteride vs finasteride: Assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or = 65 years. Am J Manag Care, 2008, 14(5 suppl 2) : s154-s159.
  • 7Kaplan SA, McConnell JD, Roehrtom CG, et al. Combination therapy with doxazosin and finastefide for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol, 20(16,175(1) : 217-221.
  • 8Roehrbom CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol, 2010, 57( 1 ) : 123-131.
  • 9Barkin J, Roehrbom CG, Siami P, et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int, 2009 , 103(7) : 919-926.
  • 10Tsukamoto T, Endo Y, Narita M. Assessment of recommended dose of dutasteride on Japanese men with benign prostatic hyperplasia: A randomized, double-blind, placebo-controlled, parallel-group, dose response study. Hinyokika Kiyo, 2009, 55(4) : 209-214.

共引文献15

同被引文献3

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部